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It has been proposed that cutaneous inflammation and 
blister formation in bullous pemphigoid is caused by 
antibodies to the cutaneous basement membrane zone 
which activate complement, thereby, attracting leuko-
cytes to the dermal-epidermal junction. There is, how-
ever, no functional evidence which supports a role for 
pemphigoid antibodies in complement activation or leu-
kocyte activity in skin. This s tudy describes the in vitro 
attachment of human peripheral blood leukocytes to the 
dermal-epidermal junction of cryostat skin se.ctions 
treated with 9/13 pemphigoid sera containing antibodies 
to the cutaneous basement membrane zone. A require-
ment for complement in the reaction was supported by 
the findings that only complement-fixing p emphigoid 
sera mediated the leukocyte response, a strong correla-
tion existed between complement-fixation titers and leu-
kocyte attachment titers and only leukocytes suspended 
in fresh serum but not buffer or heat inactivated serum 
attached at the junction. A r equirement for antibody was 
supported by the observation that IgG fractions of 4 
pemphigoid sera were as effective as whole sera in m e-
diating leukocyte attachment. The leukocyte response 
was shown to be specific for complement-fixing pemphi-
goid sera since it was not observed with noncomplement-
fixing sera or sera from 15 normal human and 22 non-
pemphigoid disease controls. This study offers functional 
evidence for an interaction between pemphigoid anti-
body, complement and leukocytes in the immunopatho-
genesis of bullous pemphigoid and demonstrates that 
complement-fixing antibasement membrane zone anti-
bodies may be important in initiating the cellular inflam-
matory events observed near the dermal-epidermaljunc-
tion in vivo. 
Bullous pemphigoid is a chronic acquired skin disease char -
acterized clinically by tense blisters and bullae which develop 
on normal, erythematous, or urticarial skin and histologically 
by dermal-epidermal separation associated with variable de-
grees of dermal inflammation [1]. While the cause of pemphi-
goid is unknown, a number of observations suggest that inflam-
matory cells are important in pathogenesis and support the 
concept that leukocyte activity contributes to separation of the 
dermal-epidermal junction. Histologic studies show a progres-
sive accumulation of leukocytes in the upper dermis and junc-
tional zone prior to blister formation and degranulation of 
Manuscript received February 8, 1980; accepted for publication April 
29, 1980. . 
This work was supported by a grant from the Dermatology Foun-
dation and by a grant from the National Institute of Arthritis, Metabolic 
and Digestive Diseases. (5-R01-AM20031) . 
Reprint requests to: Walter R. Gammon, M.D., Department of 
Dermatology, University of North Carolina, Chapel Hill, NC 27514. 
Abbreviations: 
BSA: bovine serum albumin 
GBSS: Gey's Balanced Salt Solution 
PBL: peripheral blood leukocytes 
leukocytes at the junction appears to accompany damage to 
basement membrane structures [2]. In bullous lesions, the 
blister cavity contains numerous eosinophils, neutrophils, and 
mononuclear cells and these cells may be seen infiltrating the 
dermal-epidermal junction at the edges of blisters [3]. 
Since the original report that sera of most pemphigoid pa-
tients contain antibodies directed against the basement mem-
brane zone (pemphigoid antibodies), it has been postulated that 
the cellular inflammatory events seen in the disease may have 
an antibody-mediated autoimmune pathogenesis [ 4,5]. The the-
ory has been reinforced by the observation that all patients 
with active disease have complement (C3) and most have 
immunoglobulin (lgG) deposited in a linear pattern at the 
dermal-epidermal junction in vivo [6]. Most pemphigoid sera 
contain anti-basement membrane zone antibodies capable of 
depositing and presuma bly activating complement at the der-
mal-epidermal junction in vitro [7,8]. Supporting complement 
activation in vivo is the report that heat s table complement 
derived chemotactic activity is present in pemphigoid blister 
fluids [9]. 
The similarity of the histologic and immunologic observa-
tions in pemphigoid to featmes of experimental antiglomerular 
basement membrane disease suggest that cutaneous inflam-
mation may be caused by complement fixing pemphigoid anti-
bodies binding to antigen and causing activation of the comple-
ment system at the dermal-epidermal junction [10). Comple-
ment activation may result in the formation of soluble media-
tors which directly and/or indirectly (via mast cells) cause the 
attraction and activation of leukocytes at the basement mem-
brane zone. Complement-derived mediators and immunoglob-
ulin may be responsible for triggering the release of lysosomal 
enzymes from leukocytes which may contribute to structural 
damage and separation of the dermal-epidermal junction anal-
ogous to immune-mediated injury in nephrotoxic nephritis 
[11,12). 
While the preceeding hypothesis is consistent with the re-
ported histologic and immunologic data it is unsupported by 
studies demonstrating functional activity for complement and 
antibody deposited at the dermal-epidermal junction and by 
experiments showing a relationship between antibody binding 
and leukocyte responses. This study describes a functional 
interaction between pemphigoid antibody, complement and 
leukocytes in vitro that provides additional evidence for a role 
of pemphigoid antibody in cutaneous inflammation and blister 
formation in bullous pemphigoid. 
MATERIALS AND METHODS 
Shin 
Skins were obtained immediately after routine ci.rcumcision of 
healthy human blood group 0, Rh type negative neonates. Excess fat 
and subcutaneous tissue was removed and the skin washed gently for 
10 min at 25°C in 2 changes of sterile 0.15 M NaCl buffered with .01 M 
Na.HO,, pH 7.2 (PBS), dried briefly on filter paper and cut in to 5 X 15 
mm strips. Strips were quick froze n in liquid ni trogen and mounted for 
vertical sectioning in Ames O.C.T. compound (Ames Co., Elkhart, IN) . 
All tissue blocks were frozen at -70°C un til needed for indi1·ect im-
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muno lluorescence, indirect complement fixation a nd leukocyte attach-
m en t studies. 
P emphigoid Sera. 
Serum samples conta ining a nt ibodies to the basement membrane 
zone of skin were collected from 13 patients, ages 52-84, with active 
bullous pemphigoid diagnosed by previously described cri te ria (1 3]. 
Pemphigoid ant ibody t iters were determined by indirec t immunolluo-
rescence using a previously described method (1 4]. Ti ters were found 
to range from I :10 to greater tha n 1:1280. All serum samples were 
stored at -70°C unt il needed . Prior to use samples were thawed a nd 
heat inactivated for 30 min in a 56°C water bath. 
IgG Fractions of Pemph igoid Sera. 
IgG fractions were prepared according to established methods from 
10.0 ml of each of 4 pemphigoid sera conta ining complement-fixing 
pemphigoid ant ibodies [J 5]. Briefly, crude immunoglobulin fractions 
were prepared by salt precipi tation of serum with 50% (NH4 b SO,,. 
P recipitates were washed, X2 in 25% cold (NI·t,bSO,,, dissolved in lO.O 
ml PBS dia lyzed against 3 changes of cold PBS fo r 24 hr followed by 
dia lysis against 3 cha nges of cold 0.01 M sodium phosphate pH 8.0 for 
a nother 24 hr. Samples were adjusted to 5.0 ml and layered over a 
diethyla minoethyl DE52 anion exchange column (Whatma n, Ltd. , 
K ent, England) previously equilibrated with 0.01 M sodium phosphate, 
pH 8.0. l gG was elu ted with equilibration buffer a nd first peak fractions 
concen trated on an Amicon ul trafil t ration cell , model 52 (Amicon, 
Corp., Lexington, MA.). Concentrate were dia lyzed overnight against 3 
chan ges of cold P BS and the protein concent rations were adjusted to 
10.0 and 1.0 mg/ ml. P uri ty of samples was determined by immunodif-
fusion and immunoelectrophoresis against goat a nti-huma n l gG (Hy-
la nd Labs, Costa Mesa, CA) a nd goat ant i-whole huma n serum (Gelman 
Inst. Co., Ann Arbor, Ml) using an establi heel method (16). Samples, 
tested undilu ted at both protein concentrations were fo und to conta in 
complement fixing ant i-basement membrane zone a nt ibodies. 
Control Sera 
Control sera were obta ined from 15 healthy adul ts (normal huma n 
controls) a nd 20 patients wi th a va1·iety of active inflammatory skin 
diseases other than bullous pemphigoid (disease controls). Disease 
controls included patients wi th papula r dermatit is of pregnancy, p o-
riasis, chronic muco-cutaneous candidiasis, systemic lupus erythema-
tosus, Mucha-Ha bermann disease, disseminated granuloma annula re, 
toxic epiderma l necrolysis, hyper l gE syndJ·ome, atopic dermati t is, 
nummular eczema, aph thous stomatit is, pyoderma gangrenosum, lichen 
planus and m ticarial vasculi t is. All sera were stored at- 70°C and heat 
inactivated (56°C X 30 min) prior to use. 
Complement-sufficient Serum 
Fresh-frozen, plate let-poor serum from blood group AB Rh type 
positive donors was used as a source of complement in indirect comple-
ment fi xation tests and as a suspension medium for periphera l blood 
leukocytes (PBL) in the luekocyte attachment method. P latelet poor 
serum was prepar ed according to a published method [17]. Briefly, 
blood was dJ·awn in to sterile, chilled, plastic centri fuge tubes a nd spun 
at 3500 rpm in a Sorva ll refrigerated centrifuge at 4°C for 10 min to 
remove cells and platelets. Plasma was transferred to sterile glass tubes 
a nd a llowed to clot at 25°C for 30 min. The clot was removed and 
serum a liquoted in 1 ml volumes and stored at - 70°C un t il needed. 
Serum was thawed just prior to use, kept on ice and dilu ted to 20% 
with sterile Gey's Balanced Salt Solu tion (GBSS) (Flow Labs, McLean, 
VA) , conta ining 2% bovine serum albumin (BSA) . 
Peripheral Blood Leulwcytes (PBL) 
PBL were prepared by dextran sed imenta tion of heparinized whole 
blood according to an esta blished procedure (181 from healthy adul t 
donors on no medications for at least l week p rior to blood drawing. 
Twenty ml of blood was dJ·awn and immediately anti-coagulated with 
200 uni ts of beef lung heparin (Upjohn Co., Kala mazoo, Ml) . Heparin-
ized blood was mixed thoroughly wi th an equal volume of 3% dextran 
(MW 250,000, P harmacia Co., Uppsala Sweden) and allowed to sedi-
ment at 37°C for 30 min at 1 xg. The luekocyte rich supernate was 
removed and centrifuged at 250 xg for 10 min at 25°C. Residua l .HBCs 
in the pellet were lysed by adding lO.O ml of 0.2% aqueous NaCl and 
gently mixing for 5 seconds. Isotonicity was re-esta blished by adding 
10.0 ml of 1.6% NaC I. Leukocytes were resedimented at 250 xg, sus-
pended in 2.0 ml of GBSS + 2% BSA a nd counted on a hemocytometer. 
Cells were adjusted to a concentration of 16 X 10"/ml with GBSS + 2% 
BSA. Cell viabili ty as assessed by trypan blue excl usion was always 
greater than 98%. Before adding cells to skin sections, a n equal volume 
of complement ufficient seru m was added to the cell suspension giving 
a fin al concentration of 8 x 10'; cells/ mi. 
Leukocyte Atta.chm.ent M ethod 
T he method uses blood type 0, R h type negative human skin as a 
source of basement membra ne ant igen; heat- inactivated pemphigoid 
serum, undilu ted or dilu ted with GBSS + 2% BSA as a source of anti-
basement membrane zone ant ibody; PBL from normal donors and fresh 
frozen serum from blood type AB, R h positive donors as a source of 
complement. T issue slides were prepared by placing 2-3 freshly cut 8 
1-'- cryostat sections of human skin side-by-side in the center of a sterile 
microscope slide. Sections were allowed to air dJ·y for 15 min at 25°C 
and the slides rinsed fo r 10 min in cold PBS to remove embedding 
medium a nd t issue fluids. Excess moisture was wiped away and t issue 
sections were t reated with 1 or 2 dJ·ops of heat inactivated neat or dilu te 
pemphigoid or control serum. Sections were incubated with serum for 
30 min at 4 oc in a humidi ty chamber and washed in 3 change of cold 
PBS fo r 15 min. Sections were then processed using a chamber con-
structed according to the method of Yamamoto et al as fo llows: (19]. 
E xcess PBS was removed from the slides and strips of vinyl electrical 
tape (Fisher Scient ific Co., P ittsburgh, PA) placed ru·ound each end. 
T ape strips were also placed around the ends of another microscope 
slide (covering slide) a nd the covering slide and tissue slide were taped 
together. T his created a chamber between the 2 slides in which serum-
treated skin sections were adherent to the bottom slide with a free air 
space above the tissue a nd below the covering slide (Fig 1). T he 
chamber measured .2 mm in thickness wi th a volume of approximately 
0.4 ml. PBL were dilu ted to 8 x lOn cells/ ml with 20% complement 
sufficient serum in GBSS + 2% BSA and injected with a tuberculin 
syringe in to the chamber taking car e to completely ftll the chamber 
a nd avoid air bubbles. Chambers were then incubated fo r 45 min at 
37°C in a humified a ir atmosphere using a tissue culture incubator. 
Afte r incubation, chambers were disassembled by cutting tape strips 
and nonadherent cells and excess seru m were removed by gently 
washing the slides in cold PBS for 10 min. S lides were then allowed to 
dry fo r 10-15 min at 25°C, fixed in 95% etha nol and stained with 
hematoxylin and eosin. Leukocyte attachment at the dermal-epidermal 
junction was determined by examining stained sections at 250 X with 
a Zeiss microscope. A positive reaction was recorded if cells were seen 
nonrandomly distribu ted side by side at the dermal-epidermal junction 
over more tha n 50% of the junctiona l. length in 2 skin sections. In all 
studies, both posit ive and negative controls were performed simulta-
neously, difficul t ies in in terpretation of reactions were not encountered 
(Fig 2 and 3 ar e representative of posit ive and negative leukocyte 
attachment reactions). 
Indirect Complement Fixation 
Modifications of a previously described method were used to detect 
and tite r complement- fixing pemphigoid a ntibodies in sera [7]. T hirteen 
pemphigoid sera known to conta in pemphigoid antibodies were tested 
undilu ted a nd at doubling dilu t ions fTom 1:10-1:1280. Freshly cut 8 !-'-
cryostat sections of blood type 0, R h negative neonatal foreskin were 
air-dJ·ied on glass slides a nd incubated with pemphigoid serum dilu ted 
with GBSS + 2% BSA a t 4°C in a humidity chamber for 30 min. S lides 
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FIG l. Diagram of the leukocyte attachment chamber. T he chamber 
is used for incubating serum-treated cryostat skin sections, leukocytes 
a nd complement-sufficient serum (Yamamoto et al, reference 19). 
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FIG 2. A posit ive leukocyte attachment reaction. Leukocytes (L) , 
predominantly neutrophils, can be seen side-by-side in a linear nonran-
dom distribu tion at the derma l-epiderma l junction (J) and an 8 f1. 
cryostat section of skin treated with pemphigoid serum conta ining 
complement- fixing a nt ibasement membrane zone antibodies, comple-
men t-sufficient serum and leukocytes. Randomly distribu ted leukocytes 
can be seen on the epidermis (E) and dermis (D) (reduced from X 400) . 
were then washed for 15 min in 3 changes of PBS at 25°C. Excess 
moisture was wiped from the slides and tissues incubated for 45 min 
with 1 or 2 drops of 20% complement-sufficient serum diluted with 
GBSS + 2% BSA. Slides were th en rinsed, excess moisture removed 
and treated with one drop of a 1:10 dilution of fluorescein-conjugated 
goat anti-human C3 (Hyland Labs, Costa Mesa, CA) (specific Ab 
protein cone. 150 J.Lg/ml, F .P. 3.2: 1) . S lides were incubated an additional 
30 min, rinsed and immunofluorescence read on a Zeiss fluorescent 
microscope. Complement (C3) deposition was determined by the pres-
ence of a linear band of C3 flu orescence at the dermal-epidermal 
junction. 
InteiJJretation of Data 
Statistical analysis of data was performed using Fisher's Exact T est , 
(p) Chi-square T es t <l l and Correlation Coefficient Analysis1' 1• 
RES ULTS 
Attachment of PEL at the Dermal-Epidermal Junction of 
Skin Treated with Pemphigoid Serum 
Sera containing antibodies to the cutaneous basement mem-
brane zone were selected from 13 patients with active bullous 
pemphigoid. All sera were shown by indirect immunofluores-
cence to have anti-basement membrane zone antibodies ranging 
in titer from 1:10 to greater than 1:1280. In these experiments, 
sera were tested for leukocyte attachment activity undiluted 
and a t a dilution of 1:10. Table I lists the serum antibody titers 
and results of the leukocyte attachment reaction at both con-
centrations. Nega tive sera were tested a t least twice and wexe 
found to be consistently negative. These results show that most, 
bu t not all , pemphigoid sera con taining anti-basement mem-
brane zone antibodies can mediate the attachment of PBL at 
the dermal-epidermal junction in the presence of complement-
sufficient erum. · 
Microscopic Observations of the Attachment Pattern of PEL 
at the Dermal-Epidermal Junction 
In all skin sections incubated with pemphigoid or control 
sera, a m oderat e number of leukocytes were randomly distrib-
uted over the glass slide and tissue sections. Of special interest 
was the observation that %1 pemphigoid sera caused the attach-
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ment of leukocytes (predominantly neutrophils but also eosin-
ophils and mononuclear cells) in a nonrandom linear distxibu-
tion along the dermal-epidermal junction. This pattern of cell 
attachment was apparent to observers who knew nothing of the 
study, the procedures or the results. 
In some sections treated with pemphigoid serum, a single row 
of cells was aligned side by side in the upper dermis in contact 
with the junction (Fig 2). In others, larger numbers of leuko-
cytes were crowded into the junction overlying one another and 
obscuring visualization of the upper dermis, junctional zone and 
basal layer of epidermal cells. Skin sections treated with 4 of 
the 13 pemphigoid sera did not cause leukocyte attachment as 
shown in a negative leukocyte attachment response (Fig 3) . 
Leukocyte attachment to the junction was similar to the local-
ization of leukocytes at the dermal -epidermal junction as seen 
in some biopsies of lesional pemphigoid skin (Fig 4). 
Specificity of the Attachment R eaction 
To determine if the reaction was specific for pemphigoid sera, 
sera from 15 normal donors and 22 nonpemphigoid disease 
controls were examined undiluted and diluted 1:10. In no case 
FIG 3. A negative (control) leukocyte attachment reaction on skin 
treated with normal human, nonpemphigoid disease control or noncom-
plement-fixing pemphigoid sera. Leukocytes are randomly distributed 
on the slide, epidermis (E) and dermis (D) . Only an occasional leukocyte 
can be seen at the dermal-epidermal junction (J) . (Compare to Fig 2) 
(reduced from x 250) . 
TABLE I. L eulzocyte attachment activity in 13 pemphigoid sera 
Pemphigoid antibody" Leukocyte a ttac hment'' Senun ti Le r 
undiluted diluted 1:10 
I 1/ 20 N N 
2 1/ 640 p p 
3 1/ 640 p p 
4 1/ 1280 p p 
5 1/ 1280 p p 
6 1/ 160 p p 
7 1/ 10 N N 
8 1/ 640 p p 
9 1/1280 p p 
10 1/80 N N 
11 1/ 1280 p p 
12 1/ 1280 p p 
13 1/ 10 N N 
N ""' nega tive a nd P = positive. 
"Antibody titers were determined by indirec t immunofluorescence. 
'' Attachment activity of the sera was tested neat a nd diluted 1:10 
with GBSS + 2% BSA. 
Oct. 1980 IMMUNE MEDIATED LEUKOCYTE ATTACHMENT IN SKIN 337 
was a positive response observed with either normal or disease 
controls (Table II). To insure that negative results were not a 
result of the method, a pemphigoid serum (#12) previously 
proven to mediate leukocyte attachment was used as a positive 
control with each days experiments a nd consistently showed a 
positive response. Analysis of the data (by Fisher's Exact T est) 
showed that the attachment response is specific for pemphigoid 
sera when compared to normal huma n (p < .001) or nonpem-
phigoid disease control sera (p < .001). 
Correlation Between Complement Fixation and Leulwcyte 
Attachment Titers In Bullous Pemphigoid Sera Containing 
Anti-basement M embrane Zone A ntibodies 
The 13 pemphigoid sera known to contain anti-basement 
membra ne zone antibodies were assayed simultaneously for 
complement-fixation a nd leukocyte attachment activity undi-
FIG 4. Hematoxylin and eosin section of a skin biopsy of a prebullous 
lesion from a patient with active bullous pemphigoid. Note leukocytes 
(L) infiltrating the dermal-epidermal junction and compare to leuko-
cyte attacl:unent reaction (Fig 2) M= microvesiclc. (reduced from X 
400). 
TABLE II. Comparison of bullou:; pemphigoid, normal human and 
disease control sera in mediating leukocyte attachm ent 
Serum source 
Bullous pemphigoid 
Normal human 
Nonpemphigoid disease 
controls 
Number tested 
13 
15 
22 
Results 
Positive 
9 
0 
0 
Negutive 
4 
15 
22 
luted and diluted 1:10. The tests were performed by 2 separate 
investigators (WRG & DML) without knowledge of t he other's 
results until all data were recorded and compared. As can be 
seen (Fig 5) only sera contai ning complement fixing antibase-
ment membrane antibodies were positive in t he leukocyte at-
tachment test. These results were significan t (p=.0014). 
To further establish a correlation between complement fixa-
tion and leukocyte attachment, the 9 sera positive in both tests 
were serially diluted from 1:10 to 1:1280 and the dilutions tested 
by separate investigators (WRG & DML) for complement-
fixation and leukocyte attachment activi ty. T he results of this 
study are shown in Fig 5. Figure 6 graphically demonstrates the 
high correlation between the maximum positive t iters of each 
serum in both tests. r = 0.91: 
Evidence Supporting a Role for Complement in the 
Leulwcyte Attachment R esponse 
The results of the above studies strongly suggested a role for 
complement in the reaction. To test the requirement for com-
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Ftc 5. Comparison of pemphigoid antibody, complement fixation 
and leukocyte attachment titers in 13 pemphigoid sera. Four patient's 
sera (1,7,10 and 13) had only antibody activity. The remaining 9 patients 
had similar titers of complement fixation and leukocyte attachment 
activity. 
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plement further, skin sections were treated with a pemphigoid 
serum (diluted 1:10) previously shown to mediate leukocyte 
attachment. Skin sections were subsequently exposed to washed 
PBL suspended in (a) 1:10 dilution of fresh serum (b) 1:10 
dilution of heat-inactivated (56°C X 30 min) serum or (c) buffer. 
All tests were performed in duplicate. The results showed that 
only sections treated with PBL suspended in fresh serum at-
tached at the dermal-epidermal junction. 
Evidence for Pemphigoid Antibody in Mediating Leulwcyte 
Attachment 
To support the hypothesis that antibodies were responsible 
for the leukocyte attachment activity in pemphigoid sera, im-
munochemically puTe IgG fractions from 4 sera known to pro-
mote the binding of PBL to the dermal-epidermal junction 
were obtained and tested at protein concentrations of 10 and 1 
mg/rnl. All 4 fractions were positive at both concentrations. 
Evidence Supporting A Requirement for Viable Leukocytes 
in the Attachment Response 
To test cell viability as a requirement for attachment, the 
following experiment was performed: PBL were obtained and 
divided into 3 groups of 24 X 106 cells suspended in 1 rnl of 
GBSS + 2% BSA. To group 1 was added 2 ml of GBSS + 2% 
BSA. Group 2 received 2 ml of GBSS + 2% BSA containing 2% 
sodium azide. Group 3 received 2 ml of GBSS + 2% BSA 
containing 1% sodium merthiolate. Cells were incubated at 
37°C for 1 hT, washed in GBSS + 2% BSA and tested for 
viability by trypan blue exclusion. Cell viability was greater 
than 95% for buffer-treated cells but less than 30% for cells 
treated with either merthiolate or azide. Cells were then diluted 
in 20% complement sufficient serum and tested for leukocyte 
attachment. While buffer treated cells effectively attached to 
the dermal-epidermal junction, azide and merthiolate treated 
cells did not. 
DISCUSSION 
Clinical observations of skin lesions in patients with bullous 
pemphigoid suggest an important role for inflammation in the 
pathogenesis of the disease. Types of skin lesions include ery-
thematous macules and plaques and blisters which usually arise 
on clinically inflamed skin. In some patients, one can observe a 
transition of lesions fmm ·erythematous macules to papules to 
blisters [21]. 
The histology of evolving skin lesions suggests an important 
role for cellular inflammation in their pathogenesis and evolu-
tion. Studies on the temporal sequence of histological events 
preceeding blister formation report a progressive increase in 
the number of inflammatory leukocytes infiltrating the upper 
dermis [21]. Schamburg-Lever, et a! reported a "pronounced" 
inftltrate of leukocytes in apposition to the dermal-epidermal 
junction in prebullous lesions and observed contact between 
cells and basement membrane structures prior to dermal-epi-
dermal separation [2]. Other investigators have reported the 
presence of eosinophils, neutrophils and histiocytes in close 
proximity to the junction bordering blisters and papillary micro-
abscesses in prebullous and bullous lesions [22]. Evidence sup-
porting functional activity for leukocytes is reinforced by the 
finding that degranulated cells have been observed near the 
junction [2]. 
While the histologic evidence is good that leukocytes a1·e 
important in the pathogenesis of the disease, the factors which 
initiate and regulate leukocyte responses remain obscure. A 
number of observations, however, suggest that anti-basement 
membrane antibody and complement are important in initiating 
cellular inflammation. Particularly important is the observation 
that most patients have serum antibodies reactive with a gly-
coprotein antigen located in the lamina Iucida between the 
basal cell plasma membrane and the basal lamina [4,23,24]. 
Most of these sera deposit complement in vitro at the dermal-
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epidermal junction in a pattern which corresponds exactly to 
that of antibody deposition [7,25]. Even in patients who lack 
serum antibodies, complement and usually immunoglobulins 
can be detected in the lamina Iucida, which is the ultrastructural 
site of dermal-epidermal separation [26]. 
Additional evidence supporting a role for complement in 
inflammation is the finding that multiple components of the 
classical and amplification pathways as well as complement 
regulating proteins are deposited at the dermal-epidermal junc-
tion in vivo [13,27,28,29]. In vitro studies show that comple-
ment-fixing pemphigoid antibody can deposit complement at 
the dermal-epidermal junction by the classical and amplifica-
tion pathways [30-32]. Evidence for functional complement 
activity in the disease is provided by the finding that pemphi-
goid blister fluids contain reduced levels of total hemolytic 
complement and individual component levels and increased 
amounts of complement-derived chemotactic factor activity 
[9,33]. Lacking thus far has been du·ect in vivo or in vitro 
evidence that pemphigoid antibody can interact with comple-
ment to influence cell functions which might be important in 
initiating inflammation in vivo. 
The purpose of this study was to develop a method to 
demonstrate a functional relationship between leukocyte activ-
ity and the binding of pemphigoid antibody at the dermal-
epidermal junction. To reduce nonspecific antigen-antibody 
interactions and represent as closely as possible events which 
might occur in vivo only human tissues with minimal blood 
group antigenic incompatibilities were used. Peripheral blood 
leukocytes were employed rather than emiched suspensions of 
a particular cell type since mononuclear cells and neutrophils 
as well as eosinophils have been shown to participate in the 
inflammatory response seen in lesions. 
When cryostat sections of human skin were treated with 
complement fixing pemphigoid sera, washed and subsequently 
incubated with peripheral blood leukocytes suspended in fresh 
serum, cells including neutrophils, eosinophils and mononuclear 
cells attached along the dermal-epidermal junction in a specific 
and reproducible pattern. Evidence supporting anti-basement 
membrane antibody in mediating the reaction was based on the 
findings that normal human sera and sera from patients with 
inflammatory skin diseases unassociated with anti-basement 
membrane zone antibodies did not cause leukocyte attachment. 
Additional support was provided by the finding that IgG frac-
tions of pemphigoid sera were just as effective as whole sera in 
mediating the leukocyte response. 
A role for complement in the reaction was suggested by 
several observations. Only complement fixing pemphigoid sera 
caused attachment of leukocytes and the titers of sera causing 
attachment were closely correlated with complement fixation 
titers demonstrated by indu·ect immunofluorescence. Addi-
tional evidence for a complement requirement was the obser-
vation that only leukocytes suspended in fresh serum attached 
at the dermal-epidermal junction. Cells suspended in buffer 
alone or heat inactivated serum (56°C X 30 min) did not attach. 
These studies do not precisely define the mechanism(s) of 
leukocyte attachment but do support a role for complement 
fixing antibasement membrane zone antibodies, serum comple-
ment and viable leukocytes. Any explanation of the attachment 
response would have to account for these factors. Complement-
fixing pemphigoid antibodies which are predominantly IgG 
could function in leukocyte attachment by either 1 or both of 
2 mechanisms based on knowledge of immune complex-leuko-
cyte interactions. Antibodies may play a du·ect role by opsoniz-
ing the basement membrane zone. Leukocytes could adhere to 
the Fe portion of antibody via membrane receptors for IgG Fe 
present on granulocytes [34-36] and macrophages [37,38]. Sec-
ondly, the requirement for serum complement suggests an 
additional function of antibody, deposition and activation of 
the complement system at the dermal-epidermal junction. Pem-
phigoid antibodies which have been shown in this and other 
stud ies to deposit complement at the dermal-epidermal june-
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tion could cause the formation of both solubl e and membrane-
fixed complement intermediates which could attract and me-
diate attachment of leukocytes at the junction. 
The soluble complement intermediates C3a and particularly 
C5a formed at the dermal-epidermal junction could diffuse and 
attract leukocytes to the junction by chemotaxis. Both inter-
mediates have been shown to be chemotactic for granulocytes 
and macrophages [39-41]. While chemotaxis has not been 
proven in this study, a role for leukocyte mobility can be 
inferred from the nomandom distribution of cells at the junction 
and the requi1·ement for viable cells in the attachment response. 
An additional complement dependent mechanism could re-
s ult from the formation of fixed complement intermediates at 
the junction to which leukocytes could bind. Again, granulo-
cytes and macrophages have cell membrane receptors for one 
or more complement intermediates which might be present at 
the junction [34]. Cells could, therefore, attach by complement-
dependent as well as antibody-dependent immune adherence. 
A causative role for pemphigoid antibodies capable of depos-
iting and activating complement and mediating cellular inflam-
matory events in vivo can be inferred from the results of these 
studies on pemphigoid sera. However, as shown by these and 
other studies not all pemphigoid sera contain functionally active 
antibodies. The absence of complement-fixation and leukocyte 
attachment activity in some sera may be due to the fact that all 
functionally-active antibodies have been absorbed and bound 
to the dermal-epidermal junction in vivo. It has been shown 
that pemphigoid antibodies are functionally heterogeneous and 
belong to several different IgG subclasses which vary from 
active to inactive in complement-fixation [8]. Furthermore, 
complement fiXing antibodies tend to have a higher affinity for 
antigen. These antibodies may be preferentially absorbed in 
vivo leaving only low affinity noncomplement fixing antibodies 
in the circulation. The finding that all patients do have comple-
ment deposits at the dermal-epidermal junction in vivo would 
support this contention. 
The specific mechanism of leukocyte attachment and their 
relevance to events occurring in vivo remain to be established. 
These studies do demonstrate, however, that pemphigoid anti-
body, probably through complement activation can mediate a 
specific leukocyte response in vitro. The simila1·ity of the in 
vitro response to the histology of inflammatory prebullous 
lesion in vivo can be readily appreciated. These studies add 
functional support to the histologic, immunologic and clinical 
observations that antibody and complement a1·e important in 
the inflammatory responses observed in bullous pemphigoid 
and provide additional evidence that leukocytes may mediate 
dermal-epidermal separation in the disease. 
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